10 Stocks Worth Watching This Week: AI Earnings, Jobs Data, and the Hormuz Wildcard — June 1–5, 2026
The S&P 500 just posted its ninth consecutive weekly gain. This week, a gauntlet of AI earnings, a pivotal jobs report, and simmering geopolitical risk in the Persian Gulf will determine whether the rally has room to run.
The Week Ahead: What's Moving Markets
The S&P 500 closed Friday at 7,580 — up 1.4% on the week and notching a ninth straight weekly advance, a streak not seen since late 2021. The Nasdaq outperformed, surging 2.4% to 26,973 as the AI infrastructure trade regained momentum. Dell Technologies' blowout AI server earnings on May 28 sent the stock up 33% in a single session, dragging the entire enterprise tech complex higher.
But this week brings a dense calendar that could reshape sentiment in either direction.
The data gauntlet: Monday kicks off with ISM Manufacturing PMI, followed by JOLTS job openings on Tuesday, the Fed's Beige Book and ADP private payrolls Wednesday, and the main event — Friday's May Employment Situation Report (consensus: ~95,000 nonfarm payrolls, unemployment steady at 4.3%). The labor market has been resilient but cooling, and any significant deviation from expectations will immediately reprice the probability of a June 16–17 FOMC rate cut.
Earnings: Three AI bellwethers report this week — Broadcom (Wednesday), CrowdStrike (Wednesday), and Hewlett Packard Enterprise (Monday after close). Palo Alto Networks reports Tuesday, and Credo Technology drops Q4 results tonight. This cluster will either validate the AI infrastructure supercycle narrative or inject fresh doubt.
The geopolitical overlay: U.S.-Iran negotiations remain fragile. The Strait of Hormuz — responsible for roughly 20% of global oil transit — is still functionally disrupted. Brent crude remains above $100, and any headline escalation or deal breakthrough will whipsaw energy stocks and risk appetite across the board.
Against that backdrop, here are 10 names we're watching this week — across three timeframes.
Long-Term Conviction Plays
1. Nvidia (NVDA) — $211
Category: Long-term conviction | Sector: AI Infrastructure
Nvidia remains the axis around which the entire AI economy rotates. With 80–85% market share in AI accelerators and hyperscaler capex continuing to ramp into the hundreds of billions, the structural demand story is intact and arguably still underpriced on a multi-year basis. The company's Blackwell architecture is sold out through 2027, and next-generation Rubin chips are already in design.
This week's catalyst: Every AI-adjacent earnings report this week — Broadcom, HPE, CrowdStrike, Credo — will be read as a proxy for Nvidia's ecosystem health. Strong results from these names reinforce the demand signal. Nvidia doesn't report this week, but the stock moves on ecosystem commentary as much as its own numbers.
Key risk: At ~$211, the stock has consolidated after earlier highs. Disappointing commentary from supply chain partners or a macro shock from Friday's jobs data could trigger rotation out of mega-cap tech.
2. Rheinmetall (XETRA: RHM) — €1,293
Category: Long-term conviction | Sector: Defense
The European rearmament thesis is no longer speculative — it's structural policy. NATO's new 5% of GDP target by 2035 (up from 2%) represents a generational inflection in defense procurement. Rheinmetall, as Europe's dominant munitions and armored vehicle manufacturer, sits at the center of this spending wave. The company guided for €14–14.5 billion in 2026 revenue (40–45% growth), with analyst consensus price targets averaging €2,000+, implying over 50% upside.
This week's catalyst: Ongoing U.S.-Iran conflict and Hormuz disruptions underscore the urgency of defense self-sufficiency in Europe. Any escalation this week reinforces the multi-year procurement tailwind. NATO defense ministers meet informally later this month, and pre-meeting positioning may generate headlines.
Key risk: A surprise ceasefire or Iran deal could trigger short-term profit-taking in defense names. The stock pulled back from €2,008 highs earlier this year, suggesting some investors are already tactically reducing exposure.
3. Micron Technology (MU) — $971
Category: Long-term conviction | Sector: AI / Semiconductors
Micron's ascent toward a $1 trillion market cap tells the story of the AI memory supercycle. The company's entire 2026 HBM (high-bandwidth memory) production is sold out under long-term, fixed-price contracts, providing unmatched revenue visibility. HBM4 development positions Micron for the next wave of AI accelerator architectures. Analysts have price targets ranging from $1,000 to $1,625.
This week's catalyst: Dell and HPE's AI server commentary directly impacts Micron's demand narrative. If Broadcom's Wednesday earnings show accelerating custom AI chip deployments, it further validates the memory demand runway. Micron surged 18% on May 26 after UBS lifted its target — follow-through from this week's earnings cluster could push MU above $1,000 for the first time.
Key risk: At nearly $1,000/share, the stock is priced for perfection. Any slowdown signal in AI capex — or a macro scare from weak jobs data — could trigger aggressive profit-taking. Concentration risk (dependence on a few hyperscaler customers) remains a structural concern.
4. Eli Lilly (LLY) — $1,105
Category: Long-term conviction | Sector: Healthcare / Pharma
Eli Lilly's GLP-1 franchise — Mounjaro for type 2 diabetes and Zepbound for weight loss — represents perhaps the most durable growth story in pharmaceuticals. The addressable market for GLP-1 drugs continues to expand as new indications (cardiovascular risk reduction, MASH, sleep apnea) move through trials. Revenue growth has been explosive, and manufacturing capacity is finally catching up with demand.
This week's catalyst: The macro backdrop matters here. If Friday's jobs report comes in hot, rate-cut expectations get pushed out — and defensive, high-growth healthcare names like LLY become relatively more attractive as bond yields stabilize. Additionally, any pipeline updates or FDA commentary on expanded GLP-1 indications could move the stock.
Key risk: Valuation is stretched at ~50x forward earnings. Political risk around drug pricing and potential GLP-1 access/coverage debates heading into the 2026 midterms could weigh on sentiment.
This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.
Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.